Drugs / SAPITINIB
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01330758 | Apr → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01284595 | Mar → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01003158 | Oct 2009 → Apr 2012 | breast cancer, metastatic malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00879346 | Mar → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00637039 | Feb 2008 → Jun 2009 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT00900627 | Jun 2009 → Apr 2012 | breast cancer | AstraZeneca | Completed | Missed primary |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT01862003 | May 2014 → Aug 2019 | colorectal cancer | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT02117167 | Apr 2014 → Dec 2018 | non-small cell lung carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT02299999 | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01579578 | Apr 2012 → Mar 2013 | digestive system cancer | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT01151215 | Jun 2010 → Jan 2013 | breast cancer | AstraZeneca | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01596530 Comparator | Jun 2012 → Mar 2013 | breast neoplasm | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAPITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2408045 ↗ |
| Known as | AZD8931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01151215 ↗ |
| Action | Inhibit | “AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling.” PMID 23589215 ↗ Apr 2013 |
| Modality | Small molecule | — CHEMBL2408045 ↗ |
| Route | Oral | “Patients received AZD8931 as a single oral dose” PMID 23589215 ↗ Apr 2013 |
| Target | EGFR | “inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling” PMID 23589215 ↗ Apr 2013 |
| Target | ERBB2 | “inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling” PMID 23589215 ↗ Apr 2013 |
| Target | ERBB3 | “inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling” PMID 23589215 ↗ Apr 2013 |